Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A Behavior-Integrated Potency Assay for Quantitative Evaluation of Extracellular Matrix Remodeling by Mesenchymal Stem/Stromal Cells.

Created on 06 Jul 2026

Authors

Shao Ying Tan, Mee-Hae Kim, Masahiro Kino-Oka

Published in

Biotechnology and bioengineering. Jul 05, 2026. Epub Jul 05, 2026.

Abstract

Reliable potency assays are critical for ensuring the therapeutic consistency and manufacturing quality of mesenchymal stem/stromal cells (MSCs). Conventional assays based on soluble factor quantification often fail to capture extracellular matrix (ECM) remodeling capacity and exhibit high variability. We developed a biologically relevant, image-based potency assay that directly quantifies MSCs-mediated ECM remodeling under defined biophysical conditions. A collagen-coated (CL) surface that provides a stable, proliferation-suppressive microenvironment, enabling single-cell quantification of remodeling activity using collagen hybridizing peptide staining. The ECM remodeling index (ICHP+) defined an optimal working range (3.0 × 103 ≤ cells/cm2 ≤ 4.5 × 103), where spatially separated MSCs achieved high analytical precision (CV < 10%). The CL-based assay demonstrated robust repeatability across MSCs sources and biologically relevant quantitation limits. Integration of ICHP+ with γH2AX, enabled simultaneous assessment of functional potency and cell health. Response surface methodology modeling of culture duration, seeding density, and passage number revealed a dome-shaped relationship, with maximal remodeling at early passages (Np1-Np3) and 3-5 days of culture, whereas extended culture (> 6 days) decreased potency alongside elevated γH2AX expression. The model exhibited strong predictive performance (R2 > 0.95), supporting its utility for process optimization. Collectively, this mechanism-based potency assay enables standardized platform for potency evaluation and manufacturing control for consistent, high-quality MSCs therapeutics.

PMID:
42402166
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement